Validating Your Experience with Dry Eye Syndrome
At a Glance
Dry Eye Syndrome (DES) is a chronic, multifactorial disease caused by a loss of balance in the tear film, not just a simple lack of tears. It involves a cycle of tear instability, inflammation, and nerve sensitivity, which can cause severe, legitimate pain even if the eyes appear normal.
If you have ever been told that your burning, gritty, or painful eyes are “just dry eye,” you know how dismissive that can feel. For many, Dry Eye Syndrome (DES) is not just a minor irritation; it is a chronic, legitimate disease that can fundamentally alter how you experience the world. Understanding that your experience is backed by global medical consensus is the first step toward regaining control. Return to Home
Redefining “Dryness” as a Loss of Balance
Modern medicine has moved past the idea that dry eye is simply a lack of tears. The Tear Film & Ocular Surface Society (TFOS), through their landmark DEWS II framework and recent TFOS updates, now defines it as a multifactorial disease characterized by a loss of homeostasis of the tear film [1][2].
Homeostasis refers to the healthy, stable balance your eyes need to function. When this balance is lost, it triggers a “vicious cycle” where the following four factors often feed into one another:
- Tear Film Instability: Your tears evaporate too quickly or don’t spread evenly [3].
- Hyperosmolarity: Your tears become too “salty” or concentrated, which stresses the cells on the surface of the eye [4].
- Inflammation: The eye’s surface becomes inflamed as it tries to protect itself, which further damages the tear-producing glands [5].
- Neurosensory Abnormalities: The nerves in your eyes can become hypersensitive, meaning you may feel intense pain even when the eye looks healthy to a doctor [2].
Validating Your Experience
It is common for patients to feel a “disconnect” between how their eyes feel and how they look in a mirror or to a clinician. This is now a recognized medical phenomenon. The DEWS II framework specifically accounts for cases where symptoms exist without visible surface damage, validating that your pain is real even if it isn’t “visible” [2].
Furthermore, the psychological impact of DES is significant. Research shows that patients with chronic dry eye experience higher rates of depression and anxiety than the general population [6]. The constant discomfort can lead to sleep disturbances and a reduced quality of life, affecting your ability to work, drive, and socialize [7][8].
Stabilizing Facts
To help orient yourself to this diagnosis, consider these three evidence-based facts:
- You Are Not Alone: DES is widespread. In the US, the estimated overall prevalence is approximately 3.5% for all adults, but this nearly doubles to 7.8% for those over age 68 [9][10].
- It is a Biological Continuum: Doctors now view the two main types of dry eye—aqueous deficient (not enough tears) and evaporative (tears dry too fast)—as a continuum. Most people have a blend of both rather than just one [2].
- Treatment is About Restoring Balance: Because the disease is a “loss of homeostasis,” the goal of modern treatment is not just to add moisture but to break the cycle of inflammation and restore the eye’s natural equilibrium [11][12].
The Road Ahead
While DES is a chronic condition, the release of recent TFOS guidelines represents a global effort to standardize and improve care [13]. Research is increasingly focused on personalized medicine—targeting the specific “cycle” (whether it be inflammation, nerve pain, or evaporation) that is unique to your eyes [14][15]. Knowing that there is a rigorous, international scientific framework dedicated to your condition can help you advocate for the specialized care you deserve.
Common questions in this guide
What causes dry eye syndrome?
Why do my eyes hurt even if they look normal to my doctor?
Are there different types of dry eye?
Can dry eye syndrome affect my mental health?
How is chronic dry eye treated?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Do my specific signs and symptoms suggest a loss of homeostasis in my tear film?
- 2.Which of the etiological roles—instability, hyperosmolarity, inflammation, or neurosensory abnormalities—seem most prominent in my case?
- 3.How do the recent TFOS guidelines influence the treatment path you are recommending for me?
- 4.Does the intensity of my pain match the physical signs you see, or could I be experiencing neurosensory abnormalities?
- 5.Can we discuss the emotional and psychological impact this condition is having on my daily life as part of my care plan?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (15)
- 1
TFOS DEWS III: Diagnostic Methodology.
Wolffsohn JS, Benítez-Del-Castillo JM, Loya-Garcia D, et al.
American journal of ophthalmology 2025; (279()):387-450 doi:10.1016/j.ajo.2025.05.033.
PMID: 40451408 - 2
TFOS DEWS II Definition and Classification Report.
Craig JP, Nichols KK, Akpek EK, et al.
The ocular surface 2017; (15(3)):276-283 doi:10.1016/j.jtos.2017.05.008.
PMID: 28736335 - 3
Definition and Diagnostic Criteria of Dry Eye Disease: Historical Overview and Future Directions.
Shimazaki J
Investigative ophthalmology & visual science 2018; (59(14)):DES7-DES12 doi:10.1167/iovs.17-23475.
PMID: 30481800 - 4
TFOS DEWS II pathophysiology report.
Bron AJ, de Paiva CS, Chauhan SK, et al.
The ocular surface 2017; (15(3)):438-510 doi:10.1016/j.jtos.2017.05.011.
PMID: 28736340 - 5
Ion channels in dry eye disease.
Ashok N, Khamar P, D'Souza S, et al.
Indian journal of ophthalmology 2023; (71(4)):1215-1226 doi:10.4103/IJO.IJO_3020_22.
PMID: 37026252 - 6
Dry eye disease and psychiatric disorders: A systematic review and meta-analysis.
Basilious A, Xu CY, Malvankar-Mehta MS
European journal of ophthalmology 2022; (32(4)):1872-1889 doi:10.1177/11206721211060963.
PMID: 34935549 - 7
The physical and mental burden of dry eye disease: A large population-based study investigating the relationship with health-related quality of life and its determinants.
Morthen MK, Magno MS, Utheim TP, et al.
The ocular surface 2021; (21()):107-117 doi:10.1016/j.jtos.2021.05.006.
PMID: 34044135 - 8
Association between sleep quality and corneal microstructural alterations in patients with dry eye disease: An in vivo confocal microscopy study.
Li Y, Zhu D, Ding N
Photodiagnosis and photodynamic therapy 2026; (59()):105496 doi:10.1016/j.pdpdt.2026.105496.
PMID: 42069033 - 9
Prevalence and Incidence of Dry Eye and Meibomian Gland Dysfunction in the United States: A Systematic Review and Meta-analysis.
McCann P, Abraham AG, Mukhopadhyay A, et al.
JAMA ophthalmology 2022; (140(12)):1181-1192 doi:10.1001/jamaophthalmol.2022.4394.
PMID: 36301551 - 10
Navigating Dry Eye Research: A Comprehensive Review of Etiology, Clinical Trials, Patents, and Recent Advancements.
Pal V, Verma S
Reviews on recent clinical trials 2025; (20(3)):199-210 doi:10.2174/0115748871310261240929163138.
PMID: 39410892 - 11
Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists.
Sheppard J, Shen Lee B, Periman LM
Annals of medicine 2023; (55(1)):241-252 doi:10.1080/07853890.2022.2157477.
PMID: 36576348 - 12
Efficacy of artificial tears containing trehalose and hyaluronic acid for dry eye disease in women aged 42-54 versus ≥ 55 years.
Mateo-Orobia AJ, Del Prado Sanz E, Blasco-Martínez A, et al.
Contact lens & anterior eye : the journal of the British Contact Lens Association 2023; (46(4)):101845 doi:10.1016/j.clae.2023.101845.
PMID: 37117131 - 13
TFOS DEWS III: Digest.
Stapleton F, Argüeso P, Asbell P, et al.
American journal of ophthalmology 2025; (279()):451-553 doi:10.1016/j.ajo.2025.05.040.
PMID: 40472874 - 14
Efficacy of topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in post-refractive surgery chronic dry eye patients with ocular pain.
Zhao L, Chen J, Duan H, et al.
BMC ophthalmology 2024; (24(1)):28 doi:10.1186/s12886-024-03294-z.
PMID: 38247010 - 15
Long-Term Efficacy and Safety of 0.1% Cyclosporine A Cationic Emulsion in Advanced Dry Eye Disease: A 24-Month Retrospective Study.
Sarnat-Kucharczyk M, Nowak M, Mrukwa-Kominek E
Pharmaceuticals (Basel, Switzerland) 2025; (18(11)) doi:10.3390/ph18111682.
PMID: 41304927
This page provides educational information about Dry Eye Syndrome and its symptoms. It is for informational purposes only and does not replace professional medical evaluation. Always consult an eye care specialist for diagnosis and personalized treatment.
Get notified when new evidence is published on dry eye syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.